| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/22/2001 | US6235513 IKK-α proteins, nucleic acids and methods |
| 05/22/2001 | US6235512 Nucleic acid encoding polypeptide of defined amino acid sequence which regulates transcription factor, nuclear factor kappa b, activation; hybridization probes and primers; antibodies; diagnosis; therapy |
| 05/22/2001 | US6235492 IKK-α proteins, nucleic acids and methods |
| 05/22/2001 | US6235315 Solution of lycopene, solvent and emulsifier, mixing and removal of solvent to form dry powder |
| 05/17/2001 | WO2001035106A2 Methods for identifying and using amyloid-inhibitory compounds |
| 05/17/2001 | WO2001035102A2 Diagnosis and treatment of malignant neoplasms |
| 05/17/2001 | WO2001034827A1 Antisense modulation of rank expression |
| 05/17/2001 | WO2001034802A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 05/17/2001 | WO2001034800A1 19 human secreted proteins |
| 05/17/2001 | WO2001034799A1 6 human secreted proteins |
| 05/17/2001 | WO2001034792A2 Compositions and methods for the diminution or elimination of various cancers |
| 05/17/2001 | WO2001034768A2 15 human secreted proteins |
| 05/17/2001 | WO2001034767A2 22 human secreted proteins |
| 05/17/2001 | WO2001034654A1 Hedgehog fusion proteins and uses |
| 05/17/2001 | WO2001034651A1 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents |
| 05/17/2001 | WO2001034650A1 Hgf-sf monoclonal antibody combinations |
| 05/17/2001 | WO2001034645A2 Mutated il-13 molecules and their uses |
| 05/17/2001 | WO2001034644A1 15 human secreted proteins |
| 05/17/2001 | WO2001034643A1 24 human secreted proteins |
| 05/17/2001 | WO2001034640A2 Peptide (virip) which inhibits a circulating virus in humans and the use thereof |
| 05/17/2001 | WO2001034629A1 21 human secreted proteins |
| 05/17/2001 | WO2001034628A1 35 human secreted proteins |
| 05/17/2001 | WO2001034627A1 28 human secreted proteins |
| 05/17/2001 | WO2001034623A1 29 human secreted proteins |
| 05/17/2001 | WO2001034621A1 Kringle domain-containing polynucleotides, polypeptides, and antibodies |
| 05/17/2001 | WO2001034614A2 Compositions and methods for double-targeting virus infections and targeting cancer cells |
| 05/17/2001 | WO2001034607A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 05/17/2001 | WO2001034606A1 Pharmaceutically active isoindoline derivatives |
| 05/17/2001 | WO2001034594A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| 05/17/2001 | WO2001034593A1 Compound with growth hormone releasing properties |
| 05/17/2001 | WO2001034591A2 Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 05/17/2001 | WO2001034589A1 Semi-synthesis of baccatin iii from 9-dihydro-13-acetylbaccatin iii |
| 05/17/2001 | WO2001034574A1 Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 05/17/2001 | WO2001034572A2 Carboxamide-substituted benzimidazol derivatives, method for the production thereof and their use as tryptase inhibitors |
| 05/17/2001 | WO2001034566A2 Protease inhibitors |
| 05/17/2001 | WO2001034562A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 05/17/2001 | WO2001034206A2 Nucleic acid-containing complex |
| 05/17/2001 | WO2001034205A2 Use of lytic toxins and toxin conjugates |
| 05/17/2001 | WO2001034203A1 Product inhibiting transduction of g heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 05/17/2001 | WO2001034202A2 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells |
| 05/17/2001 | WO2001034201A2 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 05/17/2001 | WO2001034194A1 Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| 05/17/2001 | WO2001034176A1 A method and composition for treating prostate cancer |
| 05/17/2001 | WO2001034174A2 Methods for administration of therapeutic agents on an antiangiogenic schedule |
| 05/17/2001 | WO2001034169A1 Use of an extract from plantago lanceolata |
| 05/17/2001 | WO2001034166A1 Transplant/implant device and method for its production |
| 05/17/2001 | WO2001034159A1 Protease inhibitors |
| 05/17/2001 | WO2001034158A1 Protease inhibitors |
| 05/17/2001 | WO2001034157A1 Protease inhibitors |
| 05/17/2001 | WO2001034145A1 Treating cancer by increasing intracellular malonyl coa levels |
| 05/17/2001 | WO2001034141A1 Il-8 receptor antagonists |
| 05/17/2001 | WO2001034137A2 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | WO2001034135A2 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | WO2001034131A2 Combination chemotherapy |
| 05/17/2001 | WO2001034130A1 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 05/17/2001 | WO2001034117A1 A method for chemoprevention of prostate cancer |
| 05/17/2001 | WO2001034116A2 Pharmaceutical formulations comprising labdanes for the treatment of tumors or leukemias |
| 05/17/2001 | WO2001034093A2 Potentiation of prodrug efficacy |
| 05/17/2001 | WO2001033942A1 Method for producing metabolites from plants cultivated in soil-less medium |
| 05/17/2001 | WO2001024796A8 1,2,4-triazole derivatives, composition, process of making and methods of use |
| 05/17/2001 | WO2001019861A3 Apo-2 receptor antibodies |
| 05/17/2001 | WO2001014358A3 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans |
| 05/17/2001 | WO2001012598A9 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 05/17/2001 | WO2001009116A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 05/17/2001 | WO2001007602A3 Oligonucleotides for inhibiting the expression of human eg5 |
| 05/17/2001 | WO2001007471A9 Cell cycle and proliferation proteins |
| 05/17/2001 | WO2001007408A3 Novel method for preparing benzoperhydroisoindole compounds |
| 05/17/2001 | WO2001005810A3 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN αVβ¿6? |
| 05/17/2001 | WO2001005427B1 Psca: prostate stem cell antigen and uses thereof |
| 05/17/2001 | WO2001005425A3 Combined preparations comprising daunorubicin derivatives and her2 antibodies |
| 05/17/2001 | WO2001004157A3 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
| 05/17/2001 | WO2000076550A3 Carrier-drug conjugate |
| 05/17/2001 | WO2000076457A3 Il-8 receptor antagonists |
| 05/17/2001 | WO2000030671A9 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
| 05/17/2001 | WO2000024755A9 Ovary-specific genes and proteins |
| 05/17/2001 | WO1999048536A3 Delivery of long lasting therapeutic agents by forming covalent attachments in vivo |
| 05/17/2001 | US20010001310 Bispecific antibodies for retargeting anticancer cytotoxic lymphocytes |
| 05/17/2001 | US20010001309 For treating pathologies related to altered alpha v beta 3 integrin-mediated cell attachment, in particular wherein inhibition of angiogenesis is desired, for example in tumors, also associated with metastasis |
| 05/17/2001 | DE19954707A1 Imidazolverbindungen als Phosphodiesterase VII-Hemmer Imidazole compounds as phosphodiesterase VII inhibitor |
| 05/17/2001 | DE19954514A1 Manipulating activity of cells ex vivo, useful e.g. in immunotherapy of cancer or viral infection, by treating the cells with antigens, adjuvants and stimulants |
| 05/17/2001 | DE19953899A1 Carboxamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Carboxamide-substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 05/17/2001 | DE19952983A1 Verfahren zum Transfer von molekularen Substanzen mit prokaryontischen nukleinsäurebindenden Proteinen A method for the transfer of molecular substances with prokaryotic nucleic acid binding proteins |
| 05/17/2001 | DE19952957A1 Modulare Transportsysteme für molekulare Substanzen und deren Herstellung und Verwendung Modular Transport systems for molecular substances and their production and use |
| 05/17/2001 | CA2404763A1 Mutated il-13 molecules and their uses |
| 05/17/2001 | CA2391416A1 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | CA2391369A1 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 05/17/2001 | CA2391277A1 Treating cancer by increasing intracellular malonyl coa levels |
| 05/17/2001 | CA2390975A1 Potentiation of prodrug efficacy |
| 05/17/2001 | CA2390880A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 05/17/2001 | CA2390834A1 Transplant/implant device and method for its production |
| 05/17/2001 | CA2390789A1 Oncolytic combinations for the treatment of cancer |
| 05/17/2001 | CA2390553A1 Pharmaceutical formulations comprising labdanes for the treatment of tumors or leukemias |
| 05/17/2001 | CA2390501A1 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells |
| 05/17/2001 | CA2390438A1 19 human secreted proteins |
| 05/17/2001 | CA2390421A1 24 human secreted proteins |
| 05/17/2001 | CA2390412A1 Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| 05/17/2001 | CA2390374A1 Diagnosis and treatment of malignant neoplasms |
| 05/17/2001 | CA2390231A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| 05/17/2001 | CA2390161A1 Methods for identifying and using amyloid-inhibitory compounds |
| 05/17/2001 | CA2389724A1 28 human secreted proteins |